747413-17-8

Basic information

• Product Name: 1-(3-broMophenyl)-4-Methylpiperazine
• Synonyms: 1-(3-broMophenyl)-4-Methylpiperazine;Piperazine,1-(3-bromophenyl)-4-methyl-;1-bromo-3-(4-methyl-1-piperazinyl)benzene
• CAS NO: 747413-17-8
• Molecular Formula: C₁₁H₁₅BrN₂
• Molecular Weight: 255.1542
• EINECS: -0
• Mol File: 747413-17-8.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(3-broMophenyl)-4-Methylpiperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3-broMophenyl)-4-Methylpiperazine(747413-17-8)
• EPA Substance Registry System: 1-(3-broMophenyl)-4-Methylpiperazine(747413-17-8)

Safety Data

• Hazardous Substances Data: 747413-17-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-(3-Bromophenyl)-4-methylpiperazine is used as a building block for the development of 4-Anilinoquinoline inhibitors of Plasmodium falciparum proliferation. These inhibitors are designed to optimize the physicochemical properties of the compounds, enhancing their effectiveness in combating the proliferation of the Plasmodium falciparum parasite, which is responsible for causing malaria. By incorporating 1-(3-Bromophenyl)-4-methylpiperazine into the molecular structure of these inhibitors, researchers can potentially improve their potency, selectivity, and pharmacokinetic properties, leading to more effective treatments for malaria.

Upstream product

• 109-01-3 1-methyl-piperazine 
• 108-36-1 1,3-dibromobenzene 
• 110-88-3 1,3,5-Trioxan 
• 31197-30-5 1-(3-bromophenyl)piperazine 
• 50-00-0 formaldehyd 
• 591-18-4 1-Bromo-3-iodobenzene 

Downstream Products

• 1139717-76-2 (3-(4-methylpiperazin-1-yl)phenyl)boronic acid 
• 1257704-57-6 {[8-(4-methanesulfonyl-phenyl)-[1,2,4]triazolo[1,5-a]-pyridin-2-yl]-[3-(4-methyl-piperazin-1-yl)-phenyl]-amine} 
• 1257704-99-6 [3-(4-methylpiperazin-1-yl)phenyl]-[8-(4-trifluoromethylphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amine 
• 1257704-81-6 [3-(4-methylpiperazin-1-yl)phenyl]-{8-[4-(propane-2-sulfonyl)phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl}amine 
• 1257709-19-5 [8-(4-fluorophenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-[3-(4-methylpiperazin-1-yl)phenyl]amine 
• 1257707-00-8 {8-[4-(dimethylphosphinoyl)phenyl]-[1,2,4]triazolo[1,5-a]-pyridin-2-yl}-[3-(4-methylpiperazin-1-yl)phenyl]amine 
• 747413-18-9 1-methyl-4-[3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)phenyl]piperazine 
• 1350659-91-4 8-fluoro-4-[5-[3-(4-methylpiperazin-1-yl)phenoxy]pyrimidin-2-yl]-3,4-dihydro-2H-benzo[1,4]oxazine 
• 1350660-04-6 1-[3-(2-chloropyrimidin-5-yloxy)phenyl]-4-methylpiperazine 
• 1286756-81-7 C₃₁H₃₁N₅O₂ 

Relevant articles and documents

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with a defect in glyoxylate metabolism, for example a disease or disorder associated with the enzyme glycolate oxidase (GO) or alterations in oxalate metabolism. Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme glycolate oxidase (GO). Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

ALKYNYL PHOSPHINE GOLD COMPLEXES FOR TREATING BACTERIAL INFECTIONS

A compound of formula (I) for use in the prevention or treatment of a bacterial infection.

Synthesis and structure-activity relationship analysis of 5-HT7 receptor antagonists: Piperazin-1-yl substituted unfused heterobiaryls

A series of piperazin-1-yl substituted unfused heterobiaryls was synthesized as ligands of the 5-HT7 receptors. The goal of this project was to elucidate the structural features that affect the 5-HT7 binding affinity of this class of compounds represented by the model ligand 4-(3-furyl)-2-(4-methylpiperazin-1-yl)pyrimidine (2). The SAR studies included systematical structural changes of the pyrimidine core moiety in 2 to quinazoline, pyridine and benzene, changes of the 3-furyl group to other heteroaryl substituents, the presence of various analogs of the 4-methylpiperazin-1-yl group, as well as additional substitutions at positions 5 and 6 of the pyrimidine. Substitution of position 6 of the pyrimidine in the model ligand with an alkyl group results in a substantial increase of the binding affinity (note a change in position numbers due to the nomenclature rules). It was also demonstrated that 4-(3-furyl) moiety is crucial for the 5-HT7 binding affinity of the substituted pyrimidines, although, the pyrimidine core can be replaced with a pyridine ring without a dramatic loss of the binding affinity. The selected ethylpyrimidine (12) and butylpyrimidine (13) analogs of high 5-HT7 binding affinity showed antagonistic properties in cAMP functional test and varied selectivity profile-compound 12 can be regarded as a dual 5-HT7 /5-HT2A R ligand, and 13 as a multi-receptor (5-HT7 , 5-HT2A , 5-HT6 and D2 ) agent.

An Improved Synthesis of the Free Base and Diglycolate Salt of CEP-33779; A Janus Kinase 2 Inhibitor

CEP-33779 is a triazole that has been reported to show highly selective inhibition of Janus kinase 2 (JAK2). An efficient process to form CEP-33779 will be presented that uses multiple palladium couplings to provide the drug substance in a convergent mann

JANUS KINASE 2 (JAK2) INHIBITOR FOR THE TREATMENT OF LUPUS

The present invention provides a method for treating lupus in a subject, comprising the step of administering to the subject COMPOUND A.

ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS

Novel, antimitotic heteroaryl amides and pharmaceutically acceptable salts of Formula I where Ar, R5, R6, R8, R9, R11, X1, and X2 are as defined herein, as compounds for treatment and prevention of cancer and proliferative diseases and disorders.

IMIDAZOLOPYRIMIDIN-2-YL DERIVATIVES AS JAK INHIBITORS

New imidazopyridmin-2-yl derivatives are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use as inhibitors of Janus Kinases (JAK) for the treatment of myeloproliferative disorders, leukemia, lymphoid malignancies and solid tumors; bone marrow and organ transplant rejection; immune-mediated diseases and inflammatory diseases.

FURO [3, 2 - B] - AND THIENO [3, 2 - B] PYRIDINE DERIVATIVES AS TBK1 AND IKK INHIBITORS

Compounds of the formula (I) in which R1, R2 and X have the meanings indicated in Claim 1, are inhibitors of TBK1 and ΙΚΚε and can be employed, inter alia, for the treatment of cancer and inflammatory diseases.